Tag
The WLM3P weight loss program significantly remodels gut microbiota, enriching beneficial bacteria such as Faecalibacterium, which associates with improved fat and visceral fat loss in adults with obesity compared to standard low-carb diets
Explore seven prevalent misconceptions about weight loss—from ignoring obesity as a disease to the dangers of rapid slimming—founded on medical evidence and expert advice to guide safe and effective weight management.
Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.
A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant associati
A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.
A 3-week ketogenic diet improved skeletal muscle insulin sensitivity and promoted weight loss in individuals with obesity, without significant effects on liver or adipose tissue insulin sensitivity.
A head-to-head comparison of ketogenic and Mediterranean diets demonstrates comparable benefits on weight, blood pressure, and metabolic health in overweight hypertensive adults over three months.
This clinical trial compares the weight loss effects of ketogenic diet, time-restricted eating, and alternate-day fasting against a Mediterranean diet in adults with obesity over three months.
Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.
Akkermansia muciniphila supplementation improves metabolic outcomes in overweight/obese type 2 diabetes patients only when baseline gut levels are low, underscoring the need for personalized microbiota-guided interventions.
High-fiber diets and supplements can aid weight management, improve metabolic health, and reduce obesity-related risks by enhancing digestion, promoting satiety, and regulating blood sugar levels.
Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.
Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.
Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.
New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.
Over 60% of liver cancer cases are preventable, yet rising obesity and metabolic dysfunction threaten progress. The Lancet Commission outlines urgent strategies to curb a projected doubling of global liver cancer burden by 2050.
A new, function-driven definition of “clinical obesity” dramatically lowers global obesity prevalence rates compared to BMI-based estimates, raising implications for disease surveillance, prevention, and healthcare policy.
Explore the impact of macronutrients on obesity, focusing on carbohydrates, proteins, and fats, and learn strategies for effective weight management.
Semaglutide drugs like Ozempic and Wegovy are transforming obesity treatment, but questions remain about long-term safety, access, and societal impact.
Exploring the science, benefits, risks, and realities behind Ozempic and other GLP-1 drugs in the fight against obesity.
